Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Articles Tagged With:

  • At press time: Cardiogenesis reports on TMR/stem cell combination

    Cardiogenesis (Irvine, California), a developer of surgical products for cardiac revascularization, reported a scientific presentation that describes the use of the Phoenix delivery system combining transmyocardial revascularization (TMR) with autologous bone marrow derived stem cells.
  • Market/technology updates: 32% of post-CABG deaths preventable

    While death rate "report cards" indicated low mortality rates after heart bypass surgery, a review of in-hospital deaths in heart bypass patients at Ontario, Canada hospitals found that one-third might have been prevented, researchers report in Circulation, the journal of the American Heart Association (Dallas).
  • Agreements

    CellCyte Genetics; Feinberg School of Medicine of Northwestern University; Digirad; Johns Hopkins University School of Medicine; IDev Technologies; YMed; Premier Purchasing Partners; GE Healthcare; Siemens Healthcare; Biosense Webster; The Sorin Group; Greatbatch; The Sorin Group
  • Business developments: Street's expectations topped by Medtronic via Endeavor launch

    Medtronic(Minneapolis) blew analysts' expectations out of the water in the latter part of May when it reported its 4Q financial results, based for the most part on the results of the initial sales of its new Endeavor drug-eluting stent (DES).
  • Pharma developments: Arterial narrowing found in study of Benicar

    A study published in a recent issue of the Journal of the American Society of Hypertension demonstrates that the hypertension treatment olmesartan medoxomil was effective in reversing the narrowing of the arteries that occurs in patients with hypertension. The study, Vascular Improvement with Olmesartan medoxomil Study (VIOS), was a one-year, exploratory trial that evaluated the effects of an angiotensin receptor blocker (olmesartan medoxomil) vs. a beta-blocker (atenolol) on vascular function and structure in patients with Stage 1 hypertension, independent of the blood pressure lowering effects of these agents.
  • Questions, but answers few concerning cardio risk, glucose control

    Diabetes and cardiovascular disease are closely linked, with a high percentage of those with diabetes dying of a cardiovascular illness or event. This is well-recognized, but the relationship between the two diseases is obviously complex.
  • Product pipeline: Siemens bills Acuson as 'paradigm shift' in ultrasound tech

    Siemens Healthcare (Mountain View, California) unveiled its Acuson SC2000 volume imaging ultrasound system, which it says is the first system to acquire non-stitched, real-time full-volume 3-D images of the heart in one single heart cycle, during the 19th annual meeting of the American Society of Echocardiography (ASE; Raleigh, North Carolina) in Toronto.
  • Personnel file

    Averion International; Boston Scientific; Cambridge Heart; CoreValve; Invatec-USA; LifeWatch; MedCath; South Dayton Surgeons; Ohio State Medical Association; Kettering Medical Center
  • Acquisitions

    AngioDynamics; Diomed Holdings; Diomed; Applera; Celera Group; Berkeley HeartLab; Boston Scientific; CryoCor; MedCath; Good Samaritan Hospital; Dayton Heart Hospital; Mindray Medical International; Datascope; Royal Philips Electronics; Dixtal Biomédica e Tecnologia; Spectranetics; Kensey Nash; Volcano; Novelis
  • International report: Approval in Japan sought for Xience V

    Abbott Vascular (Santa Clara, California) earlier this month submitted an application for Shonin marketing authorization license to Japan's Ministry of Health, Labor and Welfare/Pharmaceuticals and Medical Devices Agency to gain approval for its Xience V everolimus-eluting coronary stent system to treat coronary artery disease.